Pregabalin vs. Gabapentin on Reducing Opioid Usage

• Status: Recruiting
• Trial end date: 2022-04-12
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, randomized, open-label, Phase 4 clinical trial investigating the efficacy of multiple-dose administrations of Pregabalin or Gabapentin in combination with traditional opioid pain medications to decrease the amount of opioid pain medication usage in single-system orthopedic trauma patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CAMC Health System
• Treatments: Gabapentin; Pregabalin

Criteria

Inclusion Criteria:

1. Nurse Practitioner service admissions

2. 18 to 65 year of age

3. Patients enrolled within 24 hours of admission

4. Anticipated duration of hospitalization > 24 hours from time of consent

5. Active order(s) for opioids in place at the time of enrollment

Exclusion Criteria:

1. Clinician discretion based on patient care management

2. Intubated patients

3. Patients with epidural

4. Patients with pregabalin/gabapentin as home medications

5. Patients receiving pregabalin/gabapentin upon admission

6. Traumatic brain injury patients

7. CrCl<30ml/min or on HD

8. Unable to take enteral medications

9. On Patient Controlled Analgesia (PCA)

10. Patients with complicated wound closure

11. History of epilepsy

12. Documented history of substance use disorder